TY  - GEN
AU  - Ulaner,Gary A
AU  - Saura,Cristina
AU  - Piha-Paul,Sarina A
AU  - Mayer,Ingrid
AU  - Quinn,David
AU  - Jhaveri,Komal
AU  - Stone,Ben
AU  - Shahin,Seta
AU  - Mann,Grace
AU  - Dujka,Melanie
AU  - Bryce,Richard
AU  - Meric-Bernstam,Funda
AU  - Solit,David B
AU  - Hyman,David M
TI  - Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib
SN  - 1557-3265
PY  - 2020///1026
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Breast Neoplasms
KW  - diagnostic imaging
KW  - Breast Neoplasms, Male
KW  - Female
KW  - Fluorodeoxyglucose F18
KW  - metabolism
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Outcome Assessment, Health Care
KW  - Patient Selection
KW  - Positron-Emission Tomography
KW  - methods
KW  - Protein Kinase Inhibitors
KW  - therapeutic use
KW  - Quinolines
KW  - Radiopharmaceuticals
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-19-1658
ER  -